Back to today’s briefing

Story perspectives

Celltrion Launches Steqeyma: 85% Cheaper Biosimilar Hope

3/14/2025

50 12

Summary

Story summary

Celltrion has unveiled Steqeyma, a groundbreaking biosimilar to Janssen's Stelara, now available in the US for autoimmune diseases. With an impressive 85% lower price than Stelara, Steqeyma offers hope for patients battling conditions like plaque psoriasis and Crohn’s disease. The company is strategically pursuing contracts with key pharmacy benefit managers to boost its market presence and profitability.

1 of 1

Story summary

Celltrion has unveiled Steqeyma, a groundbreaking biosimilar to Janssen's Stelara, now available in the US for autoimmune diseases. With an impressive 85% lower price than Stelara, Steqeyma offers hope for patients battling conditions like plaque psoriasis and Crohn’s disease. The company is strategically pursuing contracts with key pharmacy benefit managers to boost its market presence and profitability.